ARS Pharmaceuticals, Inc.
SPRY
$8.25
-$0.05-0.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -13.58% | 106.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.58% | 106.79% | |||
| Cost of Revenue | -12.29% | 21.32% | |||
| Gross Profit | -14.24% | 221.87% | |||
| SG&A Expenses | -19.79% | 37.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.84% | 35.31% | |||
| Operating Income | 22.05% | -11.72% | |||
| Income Before Tax | 19.06% | -13.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.21% | -13.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.21% | -13.97% | |||
| EBIT | 22.05% | -11.72% | |||
| EBITDA | 22.26% | -11.55% | |||
| EPS Basic | 19.39% | -13.46% | |||
| Normalized Basic EPS | 28.06% | -13.46% | |||
| EPS Diluted | 18.99% | -13.46% | |||
| Normalized Diluted EPS | 28.06% | -13.46% | |||
| Average Basic Shares Outstanding | 0.22% | 0.45% | |||
| Average Diluted Shares Outstanding | 0.22% | 0.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||